Sharps Technology Shares Are Trading Higher After the Company Signed a 5-year $200 Million Syringe Sales Agreement With Nephron Pharmaceuticals.
Sharps Technology Shares Are Trading Higher After the Company Signed a 5-year $200 Million Syringe Sales Agreement With Nephron Pharmaceuticals.
夏普科技與奈弗龍製藥簽署了爲期5年的2億美元注射器銷售協議後，該公司股價走高。
Sharps Technology Shares Are Trading Higher After the Company Signed a 5-year $200 Million Syringe Sales Agreement With Nephron Pharmaceuticals.
夏普科技與奈弗龍製藥簽署了爲期5年的2億美元注射器銷售協議後，該公司股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。